Precision Oncology & Diagnostics

October 19-20,  2022 – Willis Tower, Chicago, IL

An area of explosive growth in precision medicine has been the tools to detect, identify, and categorize cancers. This growth has been especially important both for the early detection and treatment of cancer and for assisting physicians in determining the best treatments for a patient. Enabling this explosion has been an ongoing expansion in the capabilities of existing assays (e.g., transcriptomics) and the development of novel capabilities in new assays (e.g., liquid biopsies, methylation signatures). Platform technology development has fueled this growth by providing ever more sensitive measurement methods, including imaging modalities, labeling chemistries, and multi-omic profiling tools. Further empowering these developments has been the ability to analyze large, diverse, and rapidly growing datasets leading to the comprehensive classification of disease states. All these tools – assays, platforms, and datasets – have combined to drive the success of precision medicine in oncology.

Please join us for the Precision Oncology and Diagnostics Summit to hear about the expansive growth of assays, technologies, platforms, and marketplaces from leaders in biotech, pharmaceuticals, diagnostics, clinical research, healthcare and regulatory bodies.

Topics to be discussed:

  • Emerging diagnostic development platforms
  • Solid and liquid tumor acquisition and stabilization techniques and kits
  • Tumor heterogeneity – characterization for drug therapies
  • Informatics, Analytics, Signal and Image Processing
  • Genetics/Genomics
  • Proteomics/Protein-based Assays
  • Emerging ‘Omics Diagnostics
  • Gene and Protein Biomarkers
  • Augmented Intelligence for target and drug development, clinical trial design, and other areas of application
  • Partnerships among clinical laboratories, imaging technology developers, pharmas, payers, and CROs – the technological, medical, and economic ecosystem to better healthcare

Who should attend:

  • Clinicians, pathologists, histologists, diagnostics developers, AI and system software designers, payers, research scientists, or in regulatory affairs
  • Executives and Decision Makers – CEOs, CFOs, CTOs, CMOs, and CSOs
  • Payers and Insurers
  • Medical and Pharmacy Directors
  • Employer and Retiree Benefits Analysts
  • Research, Development, and Practicing Clinicians
  • Diagnostics Developers
  • Diagnostics Licensing, Sales, and Planning
  • Regulatory Leaders in Government and Business Affairs groups
  • Economic Planners and Forecasters
  • Marketing Leaders
  • Systems Developers for Systems and Software
  • Artificial and Augmented Intelligence Developers
  • Emerging ‘Omics Diagnostics in Genetics/Genomics, Proteomics/Protein-based Assays
  • Imaging label developers
  • Biomarker Research Scientists and Developers
  • Imaging platforms
  • Artificial/Augmented Intelligence, Informatics, Analytics, Signal and Image Processing